A Novel Monoclonal Management of Geriatric Osteoarthritis: Network Meta-Analysis of Comparative Efficacy and Safety of Tanezumab against Oral NSAIDs

Main Article Content

Derren David Christian Homenta Rampengan
Josh Nathaniel Jowono
Arnold Keane
Juan Alessandro Jeremis Maruli Nura Lele

Abstract

Introduction: Osteoarthritis (OA) affects approximately 250 million people worldwide and significantly causes pain and disability. Although NSAIDs are the first-line therapy, their use in geriatrics should be cautiously prescribed because of comorbidities, polypharmacy, and adverse events. Tanezumab is a humanized monoclonal IgG2 antibody that blocks NGF from activating trkA receptors on nociceptive neurons. Recent studies have shown Tanezumab as a promising candidate for enhanced clinical effects in geriatrics. However, previous meta-analyses lacked specificity for different doses of Tanezumab and did not confirm the comparison with NSAIDs.


Objective: This study aims to compare the efficacy and safety of Tanezumab with oral NSAIDs in geriatric osteoarthritis treatment.


Method: This study was conducted using the Preferred Reporting Item for Systematic Review and Meta-analysis (PRISMA). We systematically searched PubMed, ScienceDirect, and Google Scholar until April 4, 2023. The PRISMA method was done to evaluate potential bias. We performed a network meta-analysis using a random effects model that compared three doses of Tanezumab (2.5mg, 5mg, and 10mg) with NSAIDs. We measured heterogeneity using I2 and publication bias with a funnel plot.


Result: Twelve studies with a total of 7031 patients, which were screened with low risk of bias. The results showed that Tanezumab (5mg and 10mg) was the most effective for pain relief (WOMAC Pain; SMD -1.09; 95% CI -2.02 to -0.15; p = 0.002), increasing physical function (WOMAC Physical Function; SMD -5.47; 95% CI -8.71 to -2.24; p = 0.0009), and improving general health (PGA; SMD -3.83; 95% CI -6.94 to -0.72; p = 0.02). Moreover, Tanezumab was shown to be safe and associated with fewer adverse effects than NSAIDs


Conclusion: Tanezumab shows more efficacy on reducing pain, improving function, and shows less adverse effects in comparison to NSAIDs. Thus, recommended to be used for patients with inadequate reaction to therapy or comorbidities.

Article Details

How to Cite
Rampengan, D. D. C. H., Jowono, J. N., Keane, A. and Nura Lele, J. A. J. M. (2023) “A Novel Monoclonal Management of Geriatric Osteoarthritis: Network Meta-Analysis of Comparative Efficacy and Safety of Tanezumab against Oral NSAIDs”, Journal of Asian Medical Students’ Association. Kuala Lumpur, Malaysia. Available at: https://jamsa.amsa-international.org/index.php/main/article/view/645 (Accessed: 21May2024).
Section
Scientific Papers (AMSC 2023 Taiwan)

References

Hunter D, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019; 393(10182):1745-1759

Meng, Fanqiang, et al. "Efficacy and safety of biologic agents for the treatment of

osteoarthritis: A meta-analysis of randomized placebo-controlled trials." Therapeutic

Advances in Musculoskeletal Disease 14 (2022): 1759720X221080377.

Lin CL, Heron P, Hamann SR, et al. Functional distinction between NGF-mediated

plasticity and regeneration of nociceptive axons within the spinal cord. Neuroscience

; 272: 76–87.

Denk, Franziska, David L. Bennett, and Stephen B. McMahon. "Nerve growth factor

and pain mechanisms." Annual review of neuroscience 40 (2017): 307-325.

Nair AS. Tanezumab: Finally a Monoclonal Antibody for Pain Relief. Indian J Palliat

Care. 2018 Jul-Sep;24(3):384-385. doi: 10.4103/IJPC.IJPC_208_17. PMID:

; PMCID: PMC6069623.

Gao, Yijie, et al. "Efficacy and Safety of Anti–Nerve Growth Factor Antibody

Therapy for Hip and Knee Osteoarthritis: A Meta-analysis." Orthopaedic Journal of

Sports Medicine 10.4 (2022): 23259671221088590.

Kan, S. L., Li, Y., Ning, G. Z., Yuan, Z. F., Chen, L. X., Bi, M. C., et al. (2016).

Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis. PLoS One

(6), e0157105. doi:10.1371/journal.pone.0157105

Kan, S. L., Li, Y., Ning, G. Z., Yuan, Z. F., Chen, L. X., Bi, M. C., et al. (2016).

Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis. PLoS One

(6), e0157105. doi:10.1371/journal.pone.0157105

Hu, Rui, et al. Clinical outcomes of tanezumab with different dosages for patient with

osteoarthritis: network meta-analysis. Frontiers in Pharmacology 12 (2021): 614753.

Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, et al. A guide to

systematic review and meta-analysis of prognostic factor studies. BMJ [Internet].

Jan 30 [cited 2022 Oct 11];364. Available from:

https://www.bmj.com/content/364/bmj.k4597

Hochberg MC, Carrino JA, Schnitzer TJ, Guermazi A, Walsh DA, White A, et al.

Long‐term safety and efficacy of subcutaneous tanezumab versus nonsteroidal

antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial. Arthritis

Rheumatol [Internet]. 2021 Jun 7 [cited 2023 Apr 13];73(7):1167–77. Available from:

https://onlinelibrary.wiley.com/doi/10.1002/art.41674

Neogi T, Hunter DJ, Churchill M, Shirinsky I, White A, Guermazi A, et al. Observed

efficacy and clinically important improvements in participants with osteoarthritis

treated with subcutaneous tanezumab: results from a 56-week randomized

NSAID-controlled study. Arthritis Res Ther [Internet]. 2022 Mar 29 [cited 2023 Apr

;24(1):78. Available from:

https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-022-02759-0

Brown MT, Sandroni P, Low PA, Gorson KC, Hunter DJ, Pixton GC, et al.

Neurological safety of subcutaneous tanezumab versus NSAID in patients with

osteoarthritis. J Neurol Sci [Internet]. 2022 Mar [cited 2023 Apr 4];434:120184.

Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022-510X(22)00046-6

Schnitzer TJ, Bonfanti G, Atkinson J, Donevan S, Viktrup L, Barroso J, et al.

Characterizing 16-week responder profiles using group-based trajectory modeling in

over 4300 clinical trial participants receiving pharmaceutical treatment for moderate

to severe osteoarthritis. AdvTher [Internet]. 2022 Aug 12 [cited 2023 Apr

;39(10):4742–56. Available from:

https://link.springer.com/article/10.1007/s12325-022-02290-3

Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, et al. Efficacy

and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2

randomized controlled trials versus naproxen. J Rheum [Internet]. 2014 Oct 1 [cited

Apr 4];41(11):2249–59. Available from:

https://www.jrheum.org/content/41/11/2249

Schnitzer TJ, Ekman EF, Spierings ELH, Greenberg HS, Smith MD, Brown MT, et al.

Efficacy and safety of tanezumab monotherapy or combined with non-steroidal

anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann

Rheum Dis [Internet]. 2014 Mar 13 [cited 2023 Apr 4];74(6):1202–11. Available

from: https://ard.bmj.com/content/74/6/1202

Mease P, Kuritzky L, Wright WL, Mallick-Searle T, Fountaine R, Yang R, et al.

Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to

severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia:

post-hoc analysis of phase 3 trials. Curr Med Res Opin [Internet]. 2022 Aug 28 [cited

Apr 4];38(11):1909–22. Available from:

https://www.tandfonline.com/doi/abs/10.1080/03007995.2022.2113689?journalCode=

icmo20

Stanos SP, Chang WJ, Hultman C, Sadrarhami M, Yamabe T, Park P.

AB0859 improvements in physical function in patients with osteoarthritis receiving

subcutaneous tanezumab in 3 randomized controlled trials. Ann Rheum Dis [Internet].

Jun [cited 2023 Apr 13];79(Suppl 1):1736.3-1737. Available from:

https://ard.bmj.com/content/79/Suppl_1/1736.3

Hunter DJ, Schnitzer TJ, Hall J, Semel D, Davignon I, Cappelleri JC, et al. Time to

first and sustained improvement in WOMAC domains among patients with

osteoarthritis receiving tanezumab. Osteoarthr [Internet]. 2022 Sep [cited 2023 Apr

;4(3):100294. Available from:

https://linkinghub.elsevier.com/retrieve/pii/S2665913122000620

Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, et al. Effect of

tanezumab on joint pain, physical function, and patient global assessment of

osteoarthritis among patients with osteoarthritis of the hip or knee. JAMA [Internet].

Jul 2 [cited 2023 Apr 4];322(1):37. Available from:

https://jamanetwork.com/journals/jama/fullarticle/2737173

Clinicaltrials.gov. Identifier: NCT00809354 - Long-term analgesic efficacy and safety

of tanezumab alone or in combination with non-steroidal anti-inflammatory drugs

(NSAIDs) versus NSAIDs alone in patients with osteoarthritis of the knee or hip.

National Library of Medicine: Bethesda (MD); 2021 Jun 24 [cited 2023 Apr 4].

Available from: https://clinicaltrials.gov/ct2/show/NCT00809354

Clinicaltrials.gov. Identifier: NCT02528188 - Long term safety and efficacy study of

tanezumab in subjects with osteoarthritis of the hip or knee. National Library of

Medicine: Bethesda (MD); 2020 Jan 10 [cited 2023 Apr 4]. Available from:

https://clinicaltrials.gov/ct2/show/NCT02528188